Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington’s disease mouse model

The present study describes evaluation of epigenetic regulation by a small molecule as the therapeutic potential for treatment of Huntington’s disease (HD). We identified 5-allyloxy-2-(pyrrolidin-1-yl)quinoline (APQ) as a novel SETDB1/ESET inhibitor using a combined in silico and in vitro cell based...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Yu Jin, Hyeon, Seung Jae, Kim, Younghee, Lim, Sungsu, Lee, Min Young, Kim, Jieun, Londhe, Ashwini M., Gotina, Lizaveta, Kim, Yunha, Pae, Ae Nim, Cho, Yong Seo, Seong, Jihye, Seo, Hyemyung, Kim, Yun Kyung, Choo, Hyunah, Ryu, Hoon, Min, Sun-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008885/
https://www.ncbi.nlm.nih.gov/pubmed/33771089
http://dx.doi.org/10.1080/14756366.2021.1900160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008885/
https://www.ncbi.nlm.nih.gov/pubmed/33771089
http://dx.doi.org/10.1080/14756366.2021.1900160

Ejemplares similares